Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

Paul Zarogoulidis; Evaggelia Athanasiou; Theodora Tsiouda; Dimitrios Hatzibougias; Haidong Huang; Chong Bai; Georgia Trakada; Lemonia Veletza; Anastasios Kallianos; Christoforos Kosmidis; Nikolaos Barbetakis; Dimitrios Paliouras; Aggeliki Rapti; Dimitrios Drougas; Wolfgang Hohenforst-Schmidt

doi:10.1016/j.rmcr.2017.08.017

Respiratory Medicine Case Reports (Jan 2017)

Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

Paul Zarogoulidis,
Evaggelia Athanasiou,
Theodora Tsiouda,
Dimitrios Hatzibougias,
Haidong Huang,
Chong Bai,
Georgia Trakada,
Lemonia Veletza,
Anastasios Kallianos,
Christoforos Kosmidis,
Nikolaos Barbetakis,
Dimitrios Paliouras,
Aggeliki Rapti,
Dimitrios Drougas,
Wolfgang Hohenforst-Schmidt

Affiliations

Paul Zarogoulidis: Pulmonary-Oncology Unit, “Theageneio” Anticancer Hospital, Thessaloniki, Greece
Evaggelia Athanasiou: Private Pathology Center, “Microdiagnostics”, Thessaloniki, Greece
Theodora Tsiouda: Pulmonary-Oncology Unit, “Theageneio” Anticancer Hospital, Thessaloniki, Greece
Dimitrios Hatzibougias: Private Pathology Center, “Microdiagnostics”, Thessaloniki, Greece
Haidong Huang: Department of Respiratory and Critical Care Medicine, Shanghai Hospital, Second Military Medical University, Shanghai, China
Chong Bai: Department of Respiratory and Critical Care Medicine, Shanghai Hospital, Second Military Medical University, Shanghai, China
Georgia Trakada: Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
Lemonia Veletza: Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
Anastasios Kallianos: Division of Pulmonology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra Hospital, Athens, Greece
Christoforos Kosmidis: Surgery Department, “Interbalkan” European Medical Center, Thessaloniki, Greece
Nikolaos Barbetakis: Thoracic Surgery Department, “Theageneio” Anticancer Hospital, Thessaloniki, Greece
Dimitrios Paliouras: Thoracic Surgery Department, “Theageneio” Anticancer Hospital, Thessaloniki, Greece
Aggeliki Rapti: 2nd Pulmonary Department, “Sotiria” Hospital of Chest Diseases, Athens, Greece
Dimitrios Drougas: Private Scientigraphy Department, “Bioiatriki”, Thessaloniki, Greece
Wolfgang Hohenforst-Schmidt: Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, “Hof” Clinics, University of Erlangen, Hof, Germany

DOI: https://doi.org/10.1016/j.rmcr.2017.08.017
Journal volume & issue: Vol. 22, no. C
pp. 197 – 202

Abstract

Read online

In this decade a “bloom” of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targeted therapies. Immunotherapy has been well established previously for other forms of cancer, and nowadays it is also available for lung cancer. There are two immunotherapies for now nivolumab and pembrolizumab which can be administered as second line treatment, the second can also be administered as first-line if there is a programmed death-ligand 1 ≥50% expression.

Published in Respiratory Medicine Case Reports

ISSN: 2213-0071 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: http://www.journals.elsevier.com/respiratory-medicine-case-reports/

About the journal

Abstract

Keywords